Loading…
Loading…
See exactly how MSOS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MSOS and 80,000+ other tickers.
MSOS is the groundbreaking actively managed ETF, listed in the U.S., providing focused exposure exclusively to American cannabis companies, including multi-state operators. The fund's portfolio strategically allocates capital across a wide array of U.S.-based cannabis-related businesses. Offering seamless access, MSOS trades on the NYSE Arca, enabling investors to gain exposure to numerous U.S. cannabis securities through a single, convenient trade. Directly investing in individual U.S. cannabis firms often necessitates sourcing them on smaller, foreign exchanges. The ETF benefits from a…
The AdvisorShares Pure US Cannabis ETF is rated a buy, driven by real regulatory progress and potential further catalysts. Rescheduling of medical cannabis to Schedule III reduces tax burdens, improving cash flows and the cost of capital for MSOS holdings. Upcoming DEA hearings on adult-use rescheduling and earnings reports could deliver upside surprises and further margin expansion.
Owning individual U.S. cannabis operators means wrestling with OTC-listed tickers, thin liquidity, and a patchwork of state licenses that most brokerage screeners barely index.
The cannabis sector continues to attract investors seeking long-term growth opportunities in 2026. Although volatility remains high, many marijuana companies are improving operations and cutting costs. At the same time, investors continue watching potential federal reform closely. Rescheduling discussions and banking reform could become major catalysts for the industry.
Recent news of marijuana's reclassification is just the first step of many, according to Dan Ahrens of AdvisorShares. Dan talks about the catalysts he sees this summer and the upside he expects to see in marijuana-tied stocks.
Medical marijuana's US reclassification revives cannabis ETFs like WEED, with tax relief and reform hopes fueling sharp gains across the sector.